跳至主要内容
临床试验/CTRI/2022/09/045885
CTRI/2022/09/045885尚未招募2 期

SAFETY AND EFFICACY OF ORAL MIFEPRISTONE VERSUS INTRACERVICAL DINOPROSTONE GEL AS A CERVICAL RIPENING AGENT AMONG PREGNANT WOMEN REQUIRING LABOUR INDUCTION ââ?¬â?? A RANDOMIZED CONTROL TRIA

Dr P Srirohini0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Willing to participate
  • 2. Primigravida
  • 3. Singleton pregnancy,Cephalic presentation.
  • 4. Gestational age 40+ weeks.
  • 5. Maternal age >19years
  • 6. No contraindications for prostaglandins or mifepristone.
  • 7. No contraindication for vaginal delivery
  • 8. Modified Bishopââ?¬•s Score < 6
  • 9. Intact membranes.
  • 10.Women with history of 1 or 2 previous abortions.

排除标准

  • Breech presentation
  • Cephalopelvic disproportion
  • History of 3 or more abortions
  • Estimated fetal weight > 4.5 kg or < 2kg
  • Multigravida,Twin pregnancy
  • Obstetric complications like Diabetes ,Abruptio placenta or Placenta previa.
  • Abnormal fetal heart rate patterns.
  • Premature rupture of membranes.
  • Active genital infection.
  • Contraindication for mifepristone
  • Chorioamnionitis
  • Myoma or uterine anomalies
  • IVF Conception

研究者

发起方
Dr P Srirohini

相似试验